Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 416,742 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 268 · Balance 416,742 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,300 | $162.97 | $211,859.70 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 10 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,032 F9 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,300 shares in multiple trades at prices ranging from $162.80 to $163.37. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,426 | $162.17 | $231,258.70 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 9 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,332 F8 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,426 shares in multiple trades at prices ranging from $161.77 to $162.39. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,500 | $160.99 | $563,479.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 8 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,758 F7 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,500 shares in multiple trades at prices ranging from $160.70 to $161.38. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,092 | $160.25 | $1,937,743.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 7 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,258 F6 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 12,092 shares in multiple trades at prices ranging from $159.68 to $160.68. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,500 | $159.32 | $716,953.50 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,350 F5 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,500 shares in multiple trades at prices ranging from $158.68 to $159.65. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,183 | $158.09 | $1,451,777.20 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,850 F4 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 9,183 shares in multiple trades at prices ranging from $157.64 to $158.52. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,656 | $157.04 | $3,871,904.27 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,033 F3 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,656 shares in multiple trades at prices ranging from $156.63 to $157.60. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,286 | $156.09 | $3,790,826.03 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,689 F2 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,286 shares in multiple trades at prices ranging from $155.63 to $156.62. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 21,612 | $155.24 | $3,355,046.88 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,975 F1 · price: On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 21,612 shares in multiple trades at prices ranging from $154.63 to $155.61. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:37 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 103,955 | $22.00 | $2,287,010.00 |
DisclosureSEC source: 0001628280-20-017710 · wf-form4_160868024119764.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 103,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000138 · wf-form4_160037475873784.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,910 Underlying: Ordinary Shares · 103,000 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 103,000 | $99.00 | $10,197,000.00 |
DisclosureSEC source: 0001645113-20-000138 · wf-form4_160037475873784.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,632 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 103,000 | $22.00 | $2,266,000.00 |
DisclosureSEC source: 0001645113-20-000138 · wf-form4_160037475873784.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 284 | $50.41 | $14,315.02 |
DisclosureSEC source: 0001645113-20-000092 · wf-form4_159423951502640.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,632 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000032 · wf-form4_158318733739747.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,259 Underlying: Ordinary Shares · 9,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,259 | $79.45 | $735,627.55 |
DisclosureSEC source: 0001645113-20-000032 · wf-form4_158318733739747.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:19 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 53,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000016 · wf-form4_158275557536813.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 53,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:19 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Share Units | 53,333 | $88.26 | $4,707,170.58 |
DisclosureSEC source: 0001645113-20-000016 · wf-form4_158275557536813.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 21:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 155 | $52.58 | $8,150.06 |
DisclosureSEC source: 0001645113-20-000006 · wf-form4_157894985929754.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,756 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2019 through December 31, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 103,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001645113-19-000014 · wf-form4_157480367954289.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,910 Underlying: Ordinary Shares · 103,000 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 103,000 | $95.00 | $9,785,000.00 |
DisclosureSEC source: 0001645113-19-000014 · wf-form4_157480367954289.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,601 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 103,000 | $22.00 | $2,266,000.00 |
DisclosureSEC source: 0001645113-19-000014 · wf-form4_157480367954289.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $92.00 | $46,000.00 |
DisclosureSEC source: 0001209191-19-047965 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,601 Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 65,768 | $91.60 | $6,024,611.87 |
DisclosureSEC source: 0001209191-19-047965 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,101 F2 · price: On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 65,768 shares in multiple trades at prices ranging from $91.00 to $91.99. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 57,913 | $90.58 | $5,245,585.80 |
DisclosureSEC source: 0001209191-19-047965 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,869 F1 · price: On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 57,913 shares in multiple trades at prices ranging from $90.00 to $90.995. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 471 | $27.81 | $13,099.45 |
DisclosureSEC source: 0001209191-19-041555 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,782 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2019 through June 30, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2019. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 187,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-040204 · doc4.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Ordinary Shares · 187,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 187,500 | $62.15 | $11,653,125.00 |
DisclosureSEC source: 0001209191-19-040204 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 187,500 | $7.15 | $1,340,625.00 |
DisclosureSEC source: 0001209191-19-040204 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 25,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-19-038449 · doc4.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 25,000 | $61.46 | $1,536,500.00 |
DisclosureSEC source: 0001209191-19-038449 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 25,000 | $11.46 | $286,500.00 |
DisclosureSEC source: 0001209191-19-038449 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 190,338 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-037997 · doc4.xml · derivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 190,338 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 190,338 | $59.37 | $11,300,367.06 |
DisclosureSEC source: 0001209191-19-037997 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 190,338 | $14.37 | $2,735,157.06 |
DisclosureSEC source: 0001209191-19-037997 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,436 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · derivative · entry 8 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,338 Underlying: Ordinary Shares · 30,436 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 18,203 | $55.74 | $1,014,544.21 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F5 · price: On June 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 18,203 shares in multiple trades at prices ranging from $55.40 to $56.10. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,233 | $54.89 | $671,420.44 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,514 F4 · price: On June 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 12,233 shares in multiple trades at prices ranging from $54.39 to $55.38. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,436 | $14.37 | $437,365.32 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 16,835 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · derivative · entry 7 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,774 Underlying: Ordinary Shares · 16,835 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 850 | $55.43 | $47,111.25 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F3 · price: On June 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 850 shares in multiple trades at prices ranging from $55.41 to $55.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,985 | $54.71 | $874,539.35 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,161 F2 · price: On June 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 15,985 shares in multiple trades at prices ranging from $54.37 to $55.35. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 16,835 | $14.37 | $241,918.95 |
DisclosureSEC source: 0001209191-19-036764 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 35,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028873 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: Options to buy 35,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Danziger has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 115,060 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028873 · doc4.xml · derivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,060 Underlying: Ordinary Shares · 115,060 shares Expires 2029-05-08 F1 · derivative.exercise_date: Options to buy 115,060 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Danziger has been continuously employed by the Company through May 8, 2022. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:07 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 44,953 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021304 · doc4.xml · derivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,953 Underlying: Ordinary Shares · 44,953 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 44,953 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:07 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 24,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021304 · doc4.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,311 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 16,268 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-017328 · doc4.xml · derivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,609 Underlying: Ordinary Shares · 16,268 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,441 | $56.51 | $363,993.79 |
DisclosureSEC source: 0001209191-19-017328 · doc4.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,757 F4 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,441 shares in multiple trades at prices ranging from $56.39 to $56.62. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 21:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,127 | $56.00 | $343,124.25 |
DisclosureSEC source: 0001209191-19-017328 · doc4.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,198 F3 · price: On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,127 shares in multiple trades at prices ranging from $55.37 to $56.36. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.